Last reviewed · How we verify
Losartan and Amlodipine
Losartan blocks angiotensin II receptors to reduce vasoconstriction and aldosterone release, while amlodipine blocks calcium channels to relax blood vessels, together lowering blood pressure.
Losartan blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload. Used for Hypertension, Hypertension in patients with left ventricular hypertrophy.
At a glance
| Generic name | Losartan and Amlodipine |
|---|---|
| Also known as | Bicartial, Amosartan Tab. 5/50 mg, Amosartan Tab. 5/100 mg |
| Sponsor | Centro Universitario de Ciencias de la Salud, Mexico |
| Drug class | Angiotensin II receptor antagonist + Calcium channel blocker combination |
| Target | AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Losartan is an angiotensin II receptor antagonist (ARB) that prevents angiotensin II from binding to AT1 receptors, reducing peripheral vascular resistance and aldosterone-mediated sodium retention. Amlodipine is a dihydropyridine calcium channel blocker that inhibits L-type calcium influx in vascular smooth muscle, causing vasodilation. The combination provides complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension
- Hypertension in patients with left ventricular hypertrophy
Common side effects
- Dizziness
- Fatigue
- Headache
- Peripheral edema
- Hyperkalemia
Key clinical trials
- Hypertension in Young Adults Trial (PHASE2)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study) (PHASE2)
- A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial) (PHASE3)
- Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial) (PHASE2)
- Transforming Hypertension Treatment in Nigeria Using a Type II Hybrid, Interrupted Time Series Design (NA)
- Arterial Stiffness and Blood Pressure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Losartan and Amlodipine CI brief — competitive landscape report
- Losartan and Amlodipine updates RSS · CI watch RSS
- Centro Universitario de Ciencias de la Salud, Mexico portfolio CI